How to Fund a Biotech Startup (Without Killing It) | Dr. Andreas Schmidt, Springboard Health Angels

How to Fund a Biotech Startup (Without Killing It) | Dr. Andreas Schmidt, Springboard Health Angels

From building startups across three continents to backing the next generation of European biotech, Dr. Andreas Schmidt sits at the intersection of founder, operator, and investor. In this episode, he unpacks why "venture capital is the most expensive money" and when founders should avoid it, what most investors miss when evaluating early-stage biotech, and the one decision rule he uses at life's intersections — what he calls "the diving platform » moment.Dr. Andreas Schmidt is the Managing Director and Co-Founder of Springboard Health Angels, a Munich-based angel network and venture fund investing in early-stage health and life sciences companies. A serial entrepreneur with a PhD in immunology from UC Berkeley, he previously founded and scaled biotech companies in Singapore, Europe, and the US — including AYOXXA Biosystems — before turning his operator experience into capital and mentorship for the next wave of biotech founders.📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.comAndreas explains:◼️ Why "venture capital is the most expensive money" — and the underused funding paths (early revenue, family offices, matching public funds) most biotech founders ignore◼️ The "accidental marathon runner" mindset: why every biotech timeline takes twice as long as you plan, and why grit beats brilliance◼️ Why immigrants make exceptional founders — and how being thrown into "swim or sink" environments unlocks creativity most people never tap◼️ His honest take on AI-only life science startups: why he prefers companies with "hard assets" (labs, molecules, IP, clinical data) over pure-software bets◼️ The "diving platform" decision rule he uses at life's crossroads — and why standing still is the only option that never works00:00 Welcome to Transcribed00:48 What Is Springboard Health Angels? Investing with a Founder's Mindset01:27 The Jugend forscht Moment That Sparked a Science Career02:21 Why Build a Company Instead of Staying in Academia05:45 The First Company in Singapore: Sublet Rooms to Pay Employees07:10 Serial Entrepreneurship: What Nobody Tells You About the Glossy Stories08:11 What Makes Biotech Different: The Accidental Marathon Runner09:07 Can Entrepreneurship Be Learned? Why Immigrants Make Great Founders10:14 AI in Biotech: Why Hard Assets Still Matter11:37 Inside a VC's Due Diligence: What AI Can't Tell You About Founders13:22 Mentoring Founders: Seeing Yourself Across the Table15:22 Beyond Venture Capital: Mapping All the Ways to Fund a Biotech17:07 Building vs. Investing: Why Andreas Loves the Hybrid Life18:25 A Day in the Life of a VC: Fundraising, Trust, and Coffee Chats21:03 The Sparring Partner Role: Opening Doors and Sharing What Went Wrong23:12 The AYOXXA Lesson: Why the Last 0.01% Decides Everything24:06 The Most Underrated Influences: Mentors, Family, and the Boy Scouts26:12 Advice for Young People: Take Responsibility Early27:07 The Diving Platform: How to Make Life's Decisive Decisions28:32 Exponential Hype vs. Biological Reality: Will We Cure All Disease?30:00 Advice to His 25-Year-Old Self: Don't Stay on the Rails31:00 ClosingFollow Andreas:LinkedIn - https://www.linkedin.com/in/andreas-schmidt-phd-80259a/—Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com#TranscribedPodcast #Biotech #Pharma #Science #Interview #VentureCapital #Startups #AngelInvesting #SpringboardHealthAngels #Munich #Transcribed #Pierre #Meronn

Inside Europe's Biotech Powerhouse | Dr. Julia Schaft (BioRN)

As managing director of BioRN, Dr. Julia Schaft sits at the center of one of Europe's most powerful biotech ecosystems — connecting world-class research institutions, startups, and 9 of the top 20 global pharma companies within the Heidelberg region. In this episode, she unpacks why Europe keeps losing biotech companies to the US, how Germany's risk-averse culture holds back innovation, and what it actually takes to turn academic science into real products. Dr. Julia Schaft is the Managing Director of BioRN, the biotech cluster covering Heidelberg and the broader Rhein-Neckar region. She holds a PhD from EMBL and has spent over a decade building bridges between academia, industry, and policy to strengthen Germany's life science ecosystem. 📥 We distilled the sharpest lessons from our first 6 guests into one free guide — the Insider Biotech Career Starter Pack. Get it at https://transcribedpod.com Julia explains: ◼️ Why Europe has dropped from #2–3 to #7–8 globally in clinical trials — and how bureaucracy and slow processes are driving startups to the US ◼️ The "valley of death" problem: German startups get funded at the seed stage but struggle to find capital for preclinical development ◼️ Why "Americans tend to overpromise and Europeans tend to undersell" — and what that means for European science ◼️ Her honest take on AI in life sciences: "The ultimate proof that it's actually really working is still out there" ◼️ How BioRN grew from 70–80 members to 185 by creating genuine win-win collaborations instead of funding-driven alliances 00:00 Welcome to Transcribed 00:44 What Is BioRN? How a Biotech Cluster Works 01:40 A Day in the Life of a Managing Director 03:58 What Startups, Pharma, and Academia Need from BioRN 05:20 From Lab Bench to Ecosystem Builder: Julia's Career Shift 06:55 What Makes Heidelberg a Top European Biotech Hub 08:35 The Biggest Obstacles to Translating Science into Products 11:00 Is Europe Falling Behind the US and China? 13:00 Venture Capital and Risk Culture: Europe vs. America 15:40 How to Get Competitors to Actually Collaborate17:20 Talent Retention: "We Don't Need to Attract Them — We Need to Keep Them" 18:35 BioRN's Growth: From 80 Members to 185 20:07 Scientist by Heart, Networker by Evolution 21:18 AI in Life Sciences: Promise vs. Proof 23:10 Advice for Young Scientists Considering Industry 25:01 Will AI Take Away Jobs in Biotech? 26:00 Closing Follow Julia:LinkedIn - https://www.linkedin.com/in/julia-schaft-409396a/ --- Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma. 🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod📥 Free Biotech Starter Pack → https://transcribedpod.com🌐 https://transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com #TranscribedPodcast #Biotech #Pharma #Science #Interview #BioRN #Heidelberg #Startups #VentureCapital #Innovation

From CRISPR to Programmable Biology | Prof. Dominik Niopek

From dreaming of becoming a pilot to engineering proteins with light, Prof. Dr. Dominik Niopek sits at the cutting edge of programmable biology — building tools that let scientists control gene editing with a laser beam. In this episode, he walks us through how CRISPR went from a test tube experiment to an FDA-approved therapy in just 12 years, why humanoid robots might soon asist PhD students at the lab bench, and how AI is reshaping everything from protein design to how we educate the next generation of scientists.Prof. Dr. Dominik Niopek is a professor and group leader at Heidelberg University, where he runs a ~20-person lab specializing in optogenetics, CRISPR engineering, and AI-driven protein design. His work focuses on using light-sensitive proteins to precisely control genome editing and cellular processes, bridging synthetic biology and therapeutic application.Dominik explains:◼️ How his lab fuses light-sensing proteins to CRISPR tools — activating genome editing by shining a laser on a single point inside a cell◼️ Why CRISPR going from test tube to FDA-approved therapy in 12 years is "almost incomparable to anything else" in science◼️ Why humanoid robots at ~50–100K each could transform academic labs faster than traditional automation◼️ His bold vision: outsource all foundational university teaching to AI tutors so professors can focus on creative, project-based collaboration◼️ The internal reproducibility rule his lab enforces — and why it has produced near-zero complaints from collaborators00:00 Welcome to Transcribed00:45 The Boy Who Wanted to Be a Pilot02:39 The Moment Science Became an Obsession04:47 Why Scientists Should Play Piano07:15 iGEM: The Competition That Changed His Life09:58 A Day in the Life of a Professor12:06 What Is Optogenetics? Controlling Cells with Light15:09 How Running a Lab Changes as You Grow17:16 AI in the Lab: From AlphaFold to De Novo Protein Design20:39 Will AI Replace University Professors?25:00 The Hidden Risk of Trusting a Single AI27:00 CRISPR: The Biggest Biotech Revolution of Our Time30:36 The Future Lab: Humanoid Robots at the Bench33:06 The Reproducibility Crisis Is Not Over38:31 Career Advice: Follow Your Curiosity, Build Your Network40:49 ClosingFollow Dominik:LinkedIn - https://www.linkedin.com/in/dominik-niopek-796775b5/—Transcribed Podcast — in-person interviews with scientists, founders, and industry experts shaping the future of biotech and pharma.🎙️ Watch all episodes: https://www.youtube.com/@TranscribedPod🌐 transcribedpod.com📸 Instagram: @transcribedpod📧 thetranscribedpod@gmail.com#TranscribedPodcast #Biotech #Pharma #Science #Interview #CRISPR #Optogenetics #GeneTherapy #AI #Heidelberg

Can AI Cure Disease Before It Starts?

In this episode, we sit down with Dr. Abdelrahman Mahmoud, CEO & Founder of CellRewire, to explore a bold new vision for medicine: predictive and reprogrammable biology. What if AI could read the language of our cells, predict disease years before it emerges, and even reprogram cells back to a healthy state? We dive into CellRewire's groundbreaking Cell-DRL agent (Cellular Deep Reinforcement Learning), how it generates novel reprogramming therapies, and how AI can design targeted gene programs and interventions to guide diseased cells back to health.Whether you're into biotech, AI, or the future of medicine, this one's for you.Learn more about CellRewire: https://www.cellrewire.comLearn more about Transcribed: https://transcribedpod.com

CEO of PEPperPRINT: We could prevent pandemics much better.

In this episode we sit down with the CEO of PEPperPRINT Volker Stadler to explore how affordable peptide micro-arrays change the landscape of vaccine development, biotech research and more. Find us on all platforms:https://linktr.ee/transcribed_podcast#innovation #peptides #PEPperPRINT #biotech #transcribed #transcribed volker stadler #volker #stadler #Volker Stadler #podcast #biotech podcast #students #antibody #research #startup #pharma